Radionuclide therapy rapresent one of the most effective approach for the treatment of cancer. The beta-emitting radionuclide Re-188 is considered a vary attractive candidate for the development of therapeutic radiopharmaceuticals. The aim of this study was to develop the mixed-ligand [188Re(N)(SNS)(PCN)] complex using the bifunctional approach, and evaluate its stability.
New "3+1" chelating system for the development of therapeutic agents lebeled with rhenium-188.
UCCELLI, Licia;PASQUALI, Micol;BOSCHI, Alessandra;GIGANTI, Melchiore;DUATTI, Adriano
2013
Abstract
Radionuclide therapy rapresent one of the most effective approach for the treatment of cancer. The beta-emitting radionuclide Re-188 is considered a vary attractive candidate for the development of therapeutic radiopharmaceuticals. The aim of this study was to develop the mixed-ligand [188Re(N)(SNS)(PCN)] complex using the bifunctional approach, and evaluate its stability.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.